Pharmaceutical Executive
Pharmaceutical Executive
Pharmaceutical Executive Podcast
Pharmaceutical Executive Daily: FDA's new Fast-Track Review
2 minutes Posted Oct 3, 2025 at 7:47 pm.
0:00
2:49
Download MP3
Show notes
In today’s Pharmaceutical Executive Daily, we cover the FDA’s new fast-track review program for U.S.-made generics, Novartis’ FDA approval of Rhapsido for chronic spontaneous urticaria, and Halozyme’s $750 million acquisition of Elektrofi to strengthen drug delivery innovation.